{"id":"W2598236349","doi":"10.1200/jco.2015.33.15_suppl.7540","title":"Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA <i>EGFR</i> positive (IHC/FISH) non-small cell lung cancer (NSCLC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Erlotinib; Internal medicine; Clinical endpoint; Placebo; Oncology; Subgroup analysis; Randomized controlled trial; Adjuvant; Surgery; Gastroenterology; Confidence interval; Cancer; Epidermal growth factor receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002442728,0.001679987,0.00182048,0.0003750429,0.0004719768,0.0008396268,0.0009782033,0.001551256,0.005313027],"category_scores_gemma":[0.001661031,0.0005721835,0.002106048,0.0002559896,0.0007767203,0.0008196064,0.000412768,0.002494347,0.0007836373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006469585,"about_ca_system_score_gemma":0.0007484693,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000747479,"about_ca_topic_score_gemma":0.001981266,"domain_scores_codex":[0.9992889,0.000426865,0.00003145967,0.00009006116,0.00004587914,0.0001168221],"domain_scores_gemma":[0.9991265,0.0002099881,0.0002519065,0.00007258172,0.00005357872,0.0002854874],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9731498,0.006580913,0.0006589805,0.0002356798,0.0005782014,0.00003746902,0.00004063335,0.0003775984,0.00287275,0.00006244882,0.001260133,0.01414544],"study_design_scores_gemma":[0.8112839,0.1810719,0.004506995,0.00002609456,0.0005603549,0.00006464646,0.00001774421,0.0004209149,0.001025807,0.0001341258,0.0008700724,0.00001743725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890704,0.002424847,0.0006536042,0.0004514235,0.0002179075,0.00333573,0.001904776,0.0001250203,0.001816348],"genre_scores_gemma":[0.9858354,0.001052594,0.001887801,0.0009713509,0.0002635576,0.003886069,0.002615324,0.00003327951,0.003454685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005313027,"threshold_uncertainty_score":0.01777387,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1247986355711383,"score_gpt":0.4557257503106037,"score_spread":0.3309271147394655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}